Qvents

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

USFDA Warning Letter to Catalent Indiana

The USFDA has escalated the OAI (Official Action Indicated) classification of the Novo Nordisk–owned Catalent

FDA 483 to Favera, France Cites Gaps in

FDA has published the USFDA Form 483 issued to sterile drug manufacturing facility of Fareva

USFDA Updates Consideration for CES for

Biosimilarity CAA more sensitive than CES The USFDA has published a draft guidance updating scientific

CDSCO Directs Pharma Solvent Manufacture

Indian drug regulator, Central Drugs Standard Control Organisation (CDSCO) has issued new directions for stringent

FDA Classifies Novo Nordisk Plant OAI, P

Novo Nordisk’s Bloomington plant (FEI 3005949964, Catalent Indiana LLC) is classified OAI by USFDA in

Hetero Warehouse Flagged for Serious Lap

FDA conducted an inspection at the Hetero Labs Ltd, Warehouse at Nakkapally Village, Vishakapatnam, Andra

Malta Medicines Authority Maintains cGMP

Pune based Akriti Pharmaceuticals Private Limited’s EUGMP Certificate remains suspended as the facility remains in

Another Cough Syrup Fiasco

Spurious Drug  – Toxic DEG Contamination Reports of child deaths linked to contaminated cough syrups

FDA Announces Measures to Speed Up Revie

Amid all the ongoing Tariff Turf War, the U.S. Food and Drug Administration (FDA) has

Janssen Vaccine Unit Warning Letter Flag

Janssen Vaccines Corp., a Johnson & Johnson company operating in Korea, was issued an FDA